Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Phase 1 Recruiting
24 enrolled
MOUNTAINEER-03
Phase 3 Recruiting
400 enrolled
MK-3475-06C
Phase 1/2 Recruiting
160 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Phase 1 Recruiting
25 enrolled
MK-3475-C66
Phase 3 Recruiting
100 enrolled
MK-3475-06E
Phase 1/2 Recruiting
298 enrolled
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 Recruiting
40 enrolled
TRIBE-C
Phase 3 Recruiting
528 enrolled
PANCREAS
Phase 2 Recruiting
84 enrolled
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Phase 3 Recruiting
382 enrolled
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3 Recruiting
560 enrolled
FOBEAR
Phase 3 Recruiting
582 enrolled
HARMONi-GI3
Phase 3 Recruiting
600 enrolled
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Phase 3 Recruiting
408 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 2 Recruiting
180 enrolled
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
2,130 enrolled
EGRET
Phase 1 Recruiting
403 enrolled
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Phase 3 Recruiting
94 enrolled
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Phase 2 Recruiting
36 enrolled
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 Recruiting
224 enrolled
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Phase 2 Recruiting
36 enrolled
SMART TNT
Phase 1 Recruiting
25 enrolled
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/2 Recruiting
35 enrolled
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Phase 3 Recruiting
550 enrolled
LAP100
Phase 3 Recruiting
356 enrolled
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Recruiting
25 enrolled
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
Beacon-BTC
Phase 3 Recruiting
480 enrolled
MK-9999-02A
Phase 1/2 Recruiting
220 enrolled
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Phase 2 Recruiting
144 enrolled
CANTOR
Phase 2 Recruiting
120 enrolled
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Phase 3 Recruiting
300 enrolled
NEO-RT
Phase 3 Recruiting
250 enrolled
PANC
Phase 2 Recruiting
125 enrolled
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Phase 1 Recruiting
84 enrolled
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
260 enrolled
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Phase 1 Recruiting
15 enrolled
CEIL
Phase 2 Recruiting
198 enrolled
AIO-KRK-0418
Phase 3 Recruiting
507 enrolled
AtezoTRIBE2
Phase 3 Recruiting
238 enrolled
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Phase 2 Recruiting
20 enrolled
GRACIE
Phase 2 Recruiting
88 enrolled
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Phase 2 Recruiting
106 enrolled
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Phase 1 Recruiting
25 enrolled
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Phase 2 Recruiting
60 enrolled
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Phase 1 Recruiting
24 enrolled
LIBImAb
Phase 3 Recruiting
280 enrolled
BIG
Phase 2 Recruiting
120 enrolled